Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS
Status:
Not yet recruiting
Trial end date:
2029-06-30
Target enrollment:
Participant gender:
Summary
Use of magrolimab in combination with standard intensive chemotherapy ("7+3" or CPX-351) in
newly diagnosed "ELN 2022 intermediate or adverse-risk" AML or high risk MDS patients, who
intend to undergo allogeneic stem cell transplantation